 United Therapeutics Corporation NASDAQ: UTHR has presented new clinical data from the BREEZE study evaluating Tyvaso DPI treprostinil in patients with pulmonary arterial hypertension PAH. Related Content: In June FDA Accepted Tyvaso DPI Application Under Priority Review. 